Sarah Cannon Research Institute
Meredith McKean has a strong background in oncology research and medical training. Meredith began their career as an Internal Medicine Resident at the University of Colorado Anschutz Medical Campus in 2012. Meredith then pursued further specialization in oncology by completing a Hematology Oncology Fellowship at the University of Texas MD Anderson Cancer Center from 2015 to 2018. Following their fellowship, Meredith joined the Sarah Cannon Research Institute in 2018 as an Investigator in the Melanoma Research Program. Meredith later advanced to the role of Associate Director in the Melanoma and Skin Cancer Research Program in January 2021. Meredith's work experience demonstrates their dedication and expertise in the field of oncology research and patient care.
Meredith McKean has a Bachelor of Science in Biochemistry from Iowa State University. Meredith also holds a Master of Public Health degree from the University of Iowa College of Public Health. In addition, they obtained a Doctor of Medicine degree from the University of Iowa Roy J. and Lucille A. Carver College of Medicine.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.